Cost-effectiveness of Nivolumab Versus Sorafenib As First-Line Treatment for Advanced Hepatocellular Carcinoma
International Immunopharmacology（2023）
Key words
Cost-effectiveness,Hepatocellular carcinoma,Nivolumab,Partitioned survival model,Sorafenib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined